Cleo Files Patents for its Ovarian Cancer Screening Test
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Cleo Diagnostics Ltd has filed two new provisional patent applications to protect its intellectual property related to an ovarian cancer screening test. These filings focus on candidate biomarker combinations for the early detection of ovarian cancer. The company aims to establish intellectual property protection ahead of initial proof-of-concept screening data expected in the future.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from CLEO Diagnostics
- CLEO Commences Ovarian Cancer Screening Test Development
- Letter to Shareholders
- Notice of Annual General Meeting/Proxy Form
- Notice Required Under ASX Listing Rule 3.13.1
- CLIA Certified Lab selected - Pivotal US Clinical Validation
Later from CLEO Diagnostics
- CLEO Commences Analytical Validation Ahead of FDA Submission
- CLEO Screening Test Meets Rigorous Performance Targets
- Quarterly activities and cashflow report
Follow CLEO Diagnostics into a list and get an email when it puts out news.
Follow CLEO Diagnostics